Advanced Search

Show simple item record

dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKaya, Serap
dc.contributor.authorKoral, Lokman
dc.date.accessioned2024-12-16T06:21:07Z
dc.date.available2024-12-16T06:21:07Z
dc.date.issued2021en_US
dc.identifier.citationAkdeniz, N., Kaplan, M. A., Uncu, D., İnanç, M., Kaya, S., Dane, F., … Işıkdoğan, A. (2021). The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. International Journal of Colorectal Disease, 36(6), 1311–1319. https://doi.org/10.1007/s00384-021-03888-9en_US
dc.identifier.issn0179-1958 / 1432-1262
dc.identifier.urihttps://doi.org/10.1007/s00384-021-03888-9
dc.identifier.urihttps://hdl.handle.net/20.500.12428/6743
dc.description.abstractPurpose: We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC). Methods: Five hundred and seventy patients with stage III colorectal carcinoma who received different FOLFOX regimens after curative resection were included. Patients were divided into three groups as FOLFOX-4, modified FOLFOX-6 (mFOLFOX-6), and mFOLFOX-4 for comparison of toxicity and disease-free survival (DFS) and overall survival (OS) times. Results: Three-year DFS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 65%, 72%, and 72%, respectively. Five-year OS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 69%, 75%, and 67%, respectively. There was no statistically significant difference between the three treatment groups in terms of DFS and OS (p = 0.079, and p = 0.147, respectively). Among grade 1–2 adverse events (AE), thrombocytopenia, neuropathy, and stomatitis were more common in the mFOLFOX-6-treated group. The frequency of grade 1–2 nausea and vomiting were similar in mFOLFOX-6 (36.3% and 24%, respectively) and mFOLFOX-4 (32.4% and 24.7%, respectively) groups but were higher than that in the FOLFOX-4 (19.5% and 11.3%, respectively) group. Among the most common grade 3–4 AE, neutropenia (53.4%, 9%, and 13.5%, respectively) and diarrhea (10.5%, 2.2%, and 2.4, respectively) were more common in FOLFOX-4. The rate of anemia and febrile neutropenia was similar in treatment groups (p = 0.063, and p = 0.210, respectively). Conclusion: In the adjuvant treatment of stage III CRC patients, three different 5-FU administration types in FOLFOX combination treatment can be used with similar efficiency and manageable toxicity.en_US
dc.language.isoengen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvant chemotherapyen_US
dc.subjectColorectal canceren_US
dc.subjectFOLFOX regimensen_US
dc.subjectStage IIIen_US
dc.titleThe comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter studyen_US
dc.typearticleen_US
dc.authorid0000-0003-4646-4591en_US
dc.relation.ispartofInternational Journal of Colorectal Diseaseen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.identifier.volume36en_US
dc.identifier.issue6en_US
dc.institutionauthorKoral, Lokman
dc.identifier.doi10.1007/s00384-021-03888-9en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorwosidHLE-3968-2023en_US
dc.authorscopusid12783716500en_US
dc.identifier.wosqualityQ1en_US
dc.identifier.wosWOS:000617829700001en_US
dc.identifier.scopus2-s2.0-85101043431en_US
dc.identifier.pmidPMID: 33586012en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record